CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 175 target
Drug / intervention
ketoconazole +1 moredrug
Likely dose
ketoconazole 1gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00392457
NCT00392457N/ACompleted

Feedback Control of FSH Secretion in the Human Male

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·interventional·Posted Oct 26, 2006·Updated Feb 16, 2015

In Brief

A clinical study evaluating ketoconazole and gonadotropin releasing hormone (GnRH) for Kallmann Syndrome and 2 related conditions. Completed, enrolled 175 participants across 1 site.

Detailed Summary

The purpose of the research study is to learn more about the regulation of reproductive hormones in adult men. We would like to understand what role testosterone and estradiol play in controlling the release of LH (lutenizing hormone) and FSH (follicle stimulating hormone). Testosterone and estradiol come from the testes, and LH and FSH are released from a gland in the head called the pituitary. Men involved in the study will have detailed evaluations that involve overnight stays in the hospital and frequent blood sampling. The men in the study will also be receiving medications that affect the levels of various hormones in the body. This will allow the researchers to learn how various hormones influence each other. Men that participate in the study will receive medical evaluations and monetary compensation. Information gathered from this study will help in the development of new treatments for infertility and potentially new hormonal forms of contraception.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 26, 2006
Enrollment StartJul 1, 1995
Primary CompletionFeb 1, 2007
TodayJul 2, 2026
Enrollment to primary: 11.6 yearsPosted 19.7 years ago

Interventions

ketoconazoledrug

loading dose of 1g followed by a maintenance dose of 400 mg PO QID for 7 days

gonadotropin releasing hormone (GnRH)drug

Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)